moa glp 1 agonist Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics Weight Loss and Maintenance Related
Description
McEwan, P
Regulatory re-positioning of obesity as a cardiometabolic disease, payer re-classification of GLP-1 receptor agonists as essential therapies after positive cardiovascular-outcome trials, and rapid employer adoption of coverage are converging to accelerate prescription volumes
The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
By 2030, the market is set to reach $33.26 billion, maintaining a CAGR of 8.6%
2020;18(Suppl 1):18
